CTI BioPharma Statistics
Total Valuation
Genprex has a market cap or net worth of $7.66 million. The enterprise value is $4.16 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genprex has 33.15 million shares outstanding. The number of shares has increased by 406.99% in one year.
| Current Share Class | 33.15M |
| Shares Outstanding | 33.15M |
| Shares Change (YoY) | +406.99% |
| Shares Change (QoQ) | +74.88% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 5.18% |
| Float | 33.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.94
| Current Ratio | 1.94 |
| Quick Ratio | 1.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -307.08% and return on invested capital (ROIC) is -189.58%.
| Return on Equity (ROE) | -307.08% |
| Return on Assets (ROA) | -128.85% |
| Return on Invested Capital (ROIC) | -189.58% |
| Return on Capital Employed (ROCE) | -495.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.27M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.25% in the last 52 weeks. The beta is -0.48, so Genprex's price volatility has been lower than the market average.
| Beta (5Y) | -0.48 |
| 52-Week Price Change | -86.25% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.63 |
| Relative Strength Index (RSI) | 39.13 |
| Average Volume (20 Days) | 1,056,781 |
Short Selling Information
The latest short interest is 834,435, so 2.52% of the outstanding shares have been sold short.
| Short Interest | 834,435 |
| Short Previous Month | 3.32M |
| Short % of Shares Out | 2.52% |
| Short % of Float | 2.53% |
| Short Ratio (days to cover) | 0.24 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.15M |
| Pretax Income | -27.63M |
| Net Income | -19.11M |
| EBITDA | -19.14M |
| EBIT | -19.15M |
| Earnings Per Share (EPS) | -$2.58 |
Full Income StatementBalance Sheet
The company has $3.47 million in cash and n/a in debt, giving a net cash position of $3.47 million or $0.10 per share.
| Cash & Cash Equivalents | 3.47M |
| Total Debt | n/a |
| Net Cash | 3.47M |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | 3.87M |
| Book Value Per Share | 0.16 |
| Working Capital | 2.02M |
Full Balance SheetCash Flow
| Operating Cash Flow | -16.01M |
| Capital Expenditures | n/a |
| Free Cash Flow | -16.01M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
